Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110435 | 0.90 | LMNA (0.38) | KIF11MEN1ALDH1A1KMT2AADORA3 | |
| SCHEMBL5807002 | 0.79 | ALDH1A1 (0.36) | KIF11MEN1ALDH1A1KMT2A | |
| SCHEMBL5105658 | 0.79 | KIF11 (0.35) | KIF11 | |
| SCHEMBL5105664 | 0.79 | KIF11 (0.35) | KIF11 | |
| SCHEMBL4507515 | 0.76 | KIF11 (0.55) | KIF11MEN1ALDH1A1KMT2AMAP1LC3B | |
| SCHEMBL4373915 | 0.76 | ALDH1A1 (0.41) | KIF11MEN1ALDH1A1KMT2AADORA3 | |
| SCHEMBL5111419 | 0.75 | KIF11 (0.42) | KIF11MEN1ALDH1A1KMT2AADORA3 | |
| SCHEMBL4523593 | 0.72 | KIF11 (0.57) | KIF11MEN1ALDH1A1KMT2AMAP1LC3B | |
| SCHEMBL4514513 | 0.69 | KIF11 (0.54) | KIF11MEN1ALDH1A1KMT2AMAP1LC3B | |
| SCHEMBL13865434 | 0.69 | KIF11 (0.54) | KIF11MEN1ALDH1A1KMT2AMAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332498-B2 | Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives | CYTOKINETICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332498-B2 | Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives | CYTOKINETICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332498-B2 | Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives | CYTOKINETICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060111374-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-7038048-B2 | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use | CYTOKINETICS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040116438-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111374-A1 | Compounds, compositions, and methods | ALPP, MKI67, PCNA | KIF11 427/4885MEN1 1616/4885ALDH1A1 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.